Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02605616 · ClinicalTrials.gov registry record · Phase 2
Use of a Novel Drug in People With Non-alcoholic Steatohepatitis (NASH) or Non-alcoholic Fatty Liver Disease (NAFLD)
A Phase 2 study, sponsored by University of Alabama at Birmingham.
- Terminated
- Registry status
- Phase 2
- Development phase
- 93
- Enrollment target
NCT02605616 is a Phase 2 study that was terminated before completion, run by University of Alabama at Birmingham. The registered enrollment target is 93 participants.
The verdict
NCT02605616, a Phase 2 study, was terminated before completion, sponsored by University of Alabama at Birmingham.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 93 participants
- Enrollment target
Study Summary
Does the novel drug decrease liver fat in subjects with NASH or NAFLD as compared to placebo
Interventions
- OTHER Placebo
- DRUG AZ compound
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 93 participants |
| Start Date | 2015-11 |
| Est. Completion | 2019-09 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02605616
The ClinicalTrials.gov registry entry for NCT02605616 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 93 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Alabama at Birmingham, which has 1,160 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT02605616 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02605616 about?
NCT02605616 is a clinical study titled "Use of a Novel Drug in People With Non-alcoholic Steatohepatitis (NASH) or Non-alcoholic Fatty Liver Disease (NAFLD)". Does the novel drug decrease liver fat in subjects with NASH or NAFLD as compared to placebo
What is the current status of trial NCT02605616?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 93 participants. The study started on 2015-11. Estimated completion is 2019-09.
What interventions are being tested in trial NCT02605616?
The interventions under investigation include: Placebo (OTHER), AZ compound (DRUG).
Who is sponsoring clinical trial NCT02605616?
This trial is sponsored by University of Alabama at Birmingham, which has 1,160 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.